Yes, anastrozole is an aromatase inhibitor. Sold under the brand name Arimidex, it belongs to a class of drugs that block the aromatase enzyme, which is responsible for converting androgens (male-type hormones) into estrogens in the body. It’s one of three aromatase inhibitors widely used in clinical practice and is taken as a single 1 mg tablet once daily, with or without food.
How Anastrozole Blocks Estrogen Production
The aromatase enzyme normally performs a multi-step transformation that converts androgens into estrogens. This process involves modifying the hormone’s molecular structure, ultimately reshaping one of its carbon rings and releasing a small byproduct called formate. The result is a fully formed estrogen molecule ready to circulate through the body.
Anastrozole works by binding to the aromatase enzyme in a way that competes with the androgens trying to reach the same site. While it’s attached, the enzyme can’t perform its conversion job, and estrogen production drops sharply. At the standard 1 mg daily dose, anastrozole suppresses circulating estrogen levels to the limits of detection in most patients. In clinical measurements, roughly 83% of postmenopausal women on the drug had estrogen levels below what lab equipment could reliably measure.
Non-Steroidal vs. Steroidal Aromatase Inhibitors
Aromatase inhibitors fall into two categories, and the distinction matters because it affects how each drug interacts with the enzyme. Anastrozole and letrozole are non-steroidal inhibitors. They bind to aromatase competitively and reversibly, meaning they occupy the enzyme’s active site but can eventually detach. If the drug is stopped, the enzyme resumes normal function.
Exemestane, the third commonly used aromatase inhibitor, is a steroidal inhibitor. It binds irreversibly to aromatase, permanently disabling each enzyme molecule it contacts. Whether this irreversible binding translates to a meaningful clinical advantage over the reversible approach remains unclear. In practice, all three drugs achieve substantial estrogen suppression, and the choice between them often depends on side effect tolerance and individual response.
What Anastrozole Is Prescribed For
Anastrozole is FDA-approved for several breast cancer scenarios, all in postmenopausal women. Its primary use is as adjuvant treatment for hormone receptor-positive early breast cancer, meaning it’s given after surgery to reduce the risk of the cancer returning. It’s also approved as a first-line treatment for locally advanced or metastatic breast cancer that is hormone receptor-positive (or where hormone receptor status is unknown), and for advanced breast cancer that has progressed despite tamoxifen therapy.
The logic behind all three uses is the same: many breast cancers rely on estrogen to grow. By cutting off estrogen production at the source, anastrozole starves these tumors of the fuel they need. Patients whose tumors are estrogen receptor-negative rarely benefit from the drug.
Current guidelines recommend aromatase inhibitor therapy for all or part of an initial five-year course of endocrine treatment. Whether to extend treatment beyond five years is an active discussion, and recommendations vary depending on individual risk factors.
Off-Label Use in Men
Although anastrozole is approved only for breast cancer in postmenopausal women, it has a well-established off-label role in men’s health. Because men also produce estrogen through the aromatase enzyme (particularly in fat tissue), anastrozole is sometimes used to treat male infertility linked to elevated estrogen levels. Specifically, clinicians may consider it for men whose testosterone-to-estradiol ratio falls below 10, or for men with obesity who tend to have higher aromatase activity.
A retrospective study from Cleveland Clinic looked at 90 men with infertility treated with an average dose of 3 mg per week. About 46% experienced a clinically significant improvement in semen quality. The researchers suggested that clinicians could consider anastrozole for men with certain hormonal profiles before moving to more expensive alternatives. The same side effects that affect women, including reduced bone mineral density, headaches, nausea, and mood changes, apply to men as well.
Side Effects to Be Aware Of
The most significant long-term concern with anastrozole is bone health. Estrogen plays a key role in maintaining bone density, so suppressing it for months or years can lead to weaker bones and, in some cases, osteoporosis. This risk increases the longer you take the drug, and your doctor will likely monitor your bone density over the course of treatment.
Anastrozole can also raise cholesterol and blood fat levels. Joint pain and stiffness are among the most commonly reported day-to-day complaints, and they’re a frequent reason patients discuss switching to a different aromatase inhibitor or adjusting their treatment plan. Hot flashes, fatigue, and mood changes round out the typical side effect profile. Most of these effects stem directly from the drug doing exactly what it’s designed to do: lowering estrogen throughout the body, which affects tissues well beyond the breast.